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Abstract
Background: The reporting of network meta-analysis in systematic reviews has increased rapidly since 2009.
This qualitative study was undertaken to identify authors’ perceptions of the use of these methods and of what
standards for conduct and reporting should apply.
Methods: This is a survey of authors of systematic reviews reporting network meta-analysis.
Results: The response rate was 32 % of the authors contacted, with these authors responsible for 34 % of the fully
published systematic reviews identified within the period searched. Almost all authors would use the method
again. Elements of reporting standards were proposed. Responses revealed some tensions between the view that
use of network meta-analysis should be more easily accessible, particularly in the form of software tools, and
concern that there is some inappropriate use of the methods, which wider use and greater accessibility could
exacerbate.
Conclusions: Authors demonstrated strong support for adoption of standards for conduct and reporting. The
elements of reporting standards proposed are consistent with those included in the 2015 Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) extension statement. Adoption of standards for
conduct and reporting will be a significant step towards clarifying what is appropriate use of the methods and
what is not. This should be followed by the development of a critical appraisal tool to support end users of
systematic reviews reporting network meta-analysis.
Keywords: Research design/trends, Mixed treatment comparison, Evidence-based medicine, Indirect comparison,
Meta-analysis
Background
Pairwise meta-analysis remains by far the most com-
monly used method of analysis within systematic reviews
of healthcare interventions [1], outnumbering the use of
network meta-analysis by more than 20:1, but the use of
network meta-analysis (NMA) methods, including mixed
treatment comparison (MTC), is increasing rapidly [2].
These methods combine direct and indirect evidence to ad-
dress the frequent absence of randomised trials that directly
compare all the interventions of interest.
International consensus standards for the reporting of
systematic reviews and meta-analyses were developed and
published as the Quality of reporting of meta-analyses
(QUORUM) statement in 1999 [3] and updated in 2009 to
become the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement [4].
The PRISMA statement mentioned meta-analyses that
combine direct and indirect comparisons but prior to
2015 did not contain recommendations for reporting
that were specific to NMA methodology. For standards of
conduct of systematic reviews, the PRISMA statement di-
rected readers to the guidance published by The
Cochrane Collaboration [5] and the Centre for Reviews
and Dissemination [6], but each contains very limited
guidance on the use of NMA methodology in systematic
reviews. A basis for standards of conduct of NMA can be
found in the National Institute for Clinical Excellence
(NICE) Decision Support Unit’s Evidence Synthesis Tech-
nical Support Documents (TSDs) [7] and in reports on
the interpretation and conduct of MTCs published in
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and Outcomes Research (ISPOR) [8, 9]. In 2014, Hutton
[10] reported on the development of an extension to the
PRISMA statement to cover the reporting of NMA and
this extension was published in 2015 [11].
In a recent review, I reported the marked increase of
systematic reviews that report MTC or NMA since 2009
and considered potential reasons for this increased use,
including accessibility and acceptability of the
methods. I also outlined future developments that are
needed, such as consensus on standards for conduct
and reporting [2]. To explore these themes further, I
surveyed the authors of the systematic reviews included in
my review, to identify their perceptions of use of NMA
methods, particularly the standards for conduct and
reporting they think should apply. Abdelhamid [12] sur-
veyed authors of Cochrane Reviews about the use of any
indirect comparison method in systematic reviews in
2012. Only 14 % of the Cochrane reviews included in that
survey included an indirect comparison analysis, and it
was not reported whether any of these were MTC or
NMA. Additionally, only 23 % of respondents to that sur-
vey had actually ever used any indirect comparison
method. The survey reported here was not limited to
Cochrane review authors and appears to be the first of au-
thors who have published systematic reviews that report
specifically MTC or NMA.
This qualitative study was undertaken to identify au-
thors’ perceptions of the use of NMA and of what stan-
dards for conduct and reporting should apply.
Methods
The post-positivist research paradigm was adopted in
undertaking this qualitative survey. This is an interpret-
ive approach, which assumes that reality is subjective so
is an appropriate option for exploring peoples’ percep-
tions, as opposed to the positivist approach that assumes
there is an objective reality to be discovered [13]. The
methods used to identify eligible systematic reviews
are described fully in a previous publication [2]. In
summary, Medical Literature Analysis and Retrieval System
Online (MEDLINE), MEDLINE In-Process, Excerpta Med-
ica Database (EMBASE), Cumulative Index to Nursing and
Allied Health Literature (CINAHL), Database of Abstracts
of Reviews of Effects (DARE), the Cochrane Database of
Systematic Reviews, and SIGLE were searched for reviews
published up to June 2012 in which a meta-analysis had
been conducted that combined direct and indirect compar-
isons among more than two interventions. From 2318 re-
cords identified through database searching, 390 full-text
articles were assessed for eligibility and 201 of these were
included in the qualitative synthesis. One hundred fifty
seven of these were published in full and 44 as conference
abstracts, posters, or presentations.
The target sample for this survey was one author from
each of the 201 systematic reviews included in the
qualitative synthesis. The survey was conducted by email.
For ease of identifying contact details, I contacted the cor-
responding author but asked to be informed of any other
author they thought would be more appropriate to
complete the survey. When I received notification of an
email address no longer in use and was unable to identify
an alternative contact email address for the corresponding
author, I contacted the first named author as the next
preference, then second named, and so on. When I identi-
fied that a contacted author was responsible for more than
one review, I asked them to comment on each review
when answering the questions that were specific to the
review.
The survey contained eight questions (Appendix 1),
which were included in the body of the email, following
an introductory explanation regarding the background
and purpose of the survey. The email informed authors
that their responses could be quoted but would not be
attributed and identified the specific reviews each author
was being contacted about. Since this was a survey of re-
search authors, using their contact details, which were in
the public domain, asking about their research, which is
also in the public domain, consent to take part was in
the form of their choosing to reply. One reminder was
sent to each author who failed to respond and to any au-
thor who replied indicating that they would respond but
had not done so within 4 weeks or, when applicable, by
the specific time they had indicated. The survey was
conducted between March and July 2014. .In line with
National Health Service (NHS) guidance, application for
research ethics approval was not required for this survey
and I did not apply in advance of the survey for ethics
approval from my academic institution but discovered
later that I should have done. Following submission of
an application, the Research Ethics Manager, Medical
Sciences issued a confirmation letter that my study did
not raise any concerns regarding the institution’s policies
for ethics approval and approval would have been given
if my application had been submitted in advance of the
survey.
I used an Excel spreadsheet to record, for each review,
approaches to and responses from authors. Each review
was categorised by date of publication, whether it was
published in full or as a conference abstract and whether
it was reported within a primarily methodological paper.
Authors’ responses were copied into an Excel spread-
sheet before being imported to QSR Nvivo 10 for quali-
tative analysis.
Results
Figure 1 shows the number of unique authors identified
and contacted and the outcomes of contact. All ten
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authors for whom I could not identify a valid email ad-
dress were authors of one or more conference abstracts.
The 42 authors completing the survey is a response rate
of 32 %. These authors were responsible for 54 (34 %) of
the 157 fully published systematic reviews and 5 (11 %)
of the 44 reviews that were only available as conference
abstracts. Of the responses, 93 % related to reviews pub-
lished from 2009 onwards; these constituted 88 % of all
included reviews. None of the completed surveys related
to any of the four primarily methodological papers.
Why was the method chosen?
Most responses (28) cited the lack of direct comparison
data for all the interventions of interest as the reason for
conducting a NMA. Other themes were the desire to
rank interventions, the wish to try a new method due to
interest generated by other publications, and the view
that it improved the strength of the evidence. Comments
received included the following:
lack of evidence directly comparing most of the drugs
of interest
we wanted to incorporate all available evidence from
all trials whether or not they directly compared all
treatments simultaneously
Since we were comparing several competing
interventions, a methods for ranking the interventions
was intuitively preferable to preparing a series of
pairwise comparisons
The estimates of indirect comparisons can strengthen
and make more accurate the results of direct
comparisons when indirect and direct evidence are
combined in mixed treatment comparisons.
Would the author use the same method if repeating the
review?
All but one author would use the method again. That
author specified the following reason for this,
Fig. 1 Flow diagram of authors contacted and outcomes
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Because the direct result contradicted the network
analysis
Two authors stated they would carry out both direct
and indirect meta-analyses,
we indeed plan to perform a network MA again. But
we will first perform a standard MA, as this method is
more accepted, and then a NMA.
and one qualified the decision,
We would search the literature for direct
comparisons, then decide whether an indirect
comparison was still necessary
Others explained their reason for using the method
again,
it enables us to answer the questions we would
otherwise not be able to answer, that is, evaluating the
comparative effectiveness of these agents
there is no other approach that would allow
simultaneous comparison of several interventions
Was any reporting guideline followed?
More than half the responding authors (24) stated that
they had not followed any reporting guideline. Most [11]
of the other 17 respondents mentioned PRISMA [4] but
commented that it does not have content specific to this
method. Other responses mentioned publications by
ISPOR [8, 9], NICE [7], or the Australian Pharmaceutical
Benefits Advisory Committee (PBAC) [14]. Some au-
thors stated that they followed the publishing journal’s
own guideline or were guided by what other authors had
reported when publishing NMA.
What are essential details to report?
Several authors [10] specifically commented that the
same details as recommended for pairwise meta-analysis
should be included,
The paper should include all the elements required by
the PRISMA guidelines for standard MA
Others emphasised the overall purpose of reporting,
Detailed description of methods used that would
allow replication of the MTC
Some think that data files should be provided,
All data in a separate file
Raw data from the trials so that the analysis can be
replicated
The detailed reporting elements proposed by authors
are summarised in Table 1 (methodological) and Table 2
(results).
Does any reporting guideline contain the essential
details?
The most frequent response [11] to this question was
that there was not such a guideline. A few authors men-
tioned the planned extension to the PRISMA statement.
Of those who named a guideline, the most frequently
named, in decreasing order, were ISPOR [8, 9], the NICE
TSD series [7], and PRISMA [4].
What developments are needed to support conduct,
reporting, and use of the methods?
Most authors (30) stated that development and promotion
of such guidelines is needed,
development of guidelines that include all details
necessary to the performance of an indirect
comparison
Specific guidelines on how to properly report and
interpret the results of a network meta-analysis should
also be developed
Each of the following themes was raised by some
authors:
Methodological
more evidence that ranking probability is an accurate
measure
Table 1 Summary of proposed essential methodological details
to be reported
A clear research question
Search details—including terms, databases, period, language restrictions
Inclusion/exclusion criteria including whether study quality was assessed
and by what method
Assumptions
The main issue for MTCs to be valid is the consistency assumption. Very
often there is not enough information on the included studies to determine
whether the consistency assumption is actually reasonable.
Assessment that the studies are comparable. e.g. consistent endpoint
definitions, differences in patient populations or study settings are not
expected to influence the treatment effect.
Explicitly state and discuss assumptions of the analysis.
Detailed statistical analysis plan, including software; Bayesian/Frequentist
method; random/fixed effects model; code; co-variates; handling of missing
data; pooling of data; choice of priors; assessment of heterogeneity;
and assessment of consistency
sensitivity analysis of the impact of analyst assumptions is also very important.
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I believe that MTCs should only be presented as
comparative effect estimates but never as a ranking of
interventions.
Risk of bias tools
incorporate methods such as I 2 for NMA and the
incorporation of inconsistency as in the design-by-
treatment model.
a way to present results in a simple way (perhaps not
in print, but rather using animation) to include
absolute and relative effects, risk of bias, for each
outcome, with info about precision, heterogeneity and
coherence, and overall quality of evidence.
objective way of testing for convergence
inclusion of evidence from observational studies is
probably an area for development to make use of all
available evidence
Software
more easy-to-use software would be good
not requiring a higher degree in statistics to make use
of it
Improvement of available software – at the moment
WinBUGS and R are considered by many reviewers
too complex to use in routine systematic reviewing.
New/improved software needs to be more user-friendly
and less time consuming.
Training
currently few persons are able to carry out the
statistical computations, and this is limiting the
diffusion of network meta-analyses
The statistical methodology should be diffused much
more than it is today
Presentation of results
What is needed the most is a way to communicate the
findings to readers/users.
Support
access to specialist statisticians
Several authors [11] expressed concerns about widen-
ing use of the methods and evidence produced by it:
I am concerned that accessibility may be at the
expense of thinking
my concern is the unthinking use of any method
without a statistical appreciation of the model(s) and
the assumptions
Particularly when they use rankings, the information
is often misleading because readers tend to focus on
the top intervention
Nowadays people “believe” in MA as if it were the
absolute truth, not understanding that there are good
quality and poor quality MA. And same with network
MA, but the risk is even higher in this latter case.
These methods are becoming increasingly popular,
and there are many examples of poorly performed
analyses
There are many subtleties and underlying
assumptions in performing such an analysis, and
increasingly there are many “automated” analysis,
where data are pulled from papers and fed into
computer programs, with poor assessment or even
identification of assumptions.
those publishing indirect comparisons understand
how to assess their quality
stricter editorial processes to ensure adherence to
systematic review, statistical and reporting standards
those utilizing indirect comparisons in their decision-
making are able to recognize when they are performed
correctly and can be confident in their results
The problem of network meta-analyses and indirect
comparisons is that the statistical methods are diffi-
cult for most readers to understand or reproduce.
Therefore, it is a black box.
I believe the use of it should be determined via the
careful judgement of whether it is really needed, not
Table 2 Summary of proposed essential result details to be
reported
Details of included studies
numbers of included studies for each direct comparison; numbers of
subjects for each treatment
study bias assessment
the quality assessment of included studies
Details relating to the network
Network diagram including the number of trials included in each link
Sources of heterogeneity must be assessed and the impact of heterogeneity
must be analysed.
Evaluation of the “confidence” in the network (amount of evidence,
homogeneity, consistency)
How good a fit the chosen model is to the data set.
Details relating to effect estimates
point estimates and confidence/credible intervals
95 % credible intervals/probability intervals must be included when
reporting the effect estimate
absolute effect of each intervention [when reporting input parameters of
economic modelling]
reporting of estimates and variances of the direct comparisons that form
the indirect comparison
Comparison of results from direct evidence with results from NMA
Sensitivity analyses if necessary, and an explanation of the differences
compared with standard MA
The key information needed is to provide separately the direct and indirect
estimates, and try to provide the quality of evidence supporting each
rankings [perhaps rankograms as well] and probabilities of each
intervention being best.
For Bayesian mixed treatment comparisons: Probability Rankograms and
Surface Under Cumulative Ranking Curve
Well reasoned sensitivity analysis, including/excluding different data sources.
Lee Systematic Reviews  (2016) 5:8 Page 5 of 8
just 'encouraged' regardless of the research question
and the level of parameter heterogeneity.
What would encourage more use of the methods by
systematic reviewers?
Guidelines were again a common theme in response to
this question, alongside greater perceived acceptability of
use of these methods, particularly through endorsement
by key organisations and increased likelihood of
publication,
Guidelines would help
promotion of guidelines etc to Cochrane review
groups
Uptake would also be increased if HTA organisations
other than NICE gave explicit statements on the
acceptability of indirect comparisons and NMA and
issued guidance.
Less scepticism by the methods community.
Increased likelihood of publication
Stronger journal policies encouraging its use.
Other themes were training, software development,
and access to statistical expertise:
Training
Reviewers need to be educated in the proper
performance and reporting of indirect comparisons.
More broadly, they need to be educated that such
methods exist and can be used to derive answers
unattainable by other methods.
The knowledge of the method, of its possibilities, aims
and limits would encourage the reviewers to use MTC
Understanding of assumptions and pitfalls to give
more confidence in the use of the method.
Better understanding of indirect comparison methods,
and their comparability with ‘classical’ meta-analysis.
The reviewers need to understand the advantages of
such methods, and the fact that most limitations of
the indirect comparison methods are indeed limita-
tions of the classical direct comparison methods as
well.
Software
Software has to become more user-friendly.
easy frequentist software
Standard code for different situations
Statistical expertise
Currently, the statistical expertise necessary is the
main limitation
What would encourage more use of the methods by
decision makers?
Training was again a clear theme,
Again, education is key. Indirect comparisons can
be performed well or poorly, and exposure to well-
performed indirect comparisons and education in how
to identify one that has been performed poorly will
enable decision makers to broaden the array of evidence
that they can use to support their decisions.
including tutorial articles explaining the basic premise
in non-technical language and individual applications
explaining their methods and results in a way that is
accessible to wider readers.
There was mixed opinion regarding the desirability of
this aspect of increased use.
I would not encourage it for the sake of it. I think
there are situations where it would be better avoided,
e.g. where there is robust direct evidence.
the methods are complex and it would be very
difficult for someone without extensive technical
expertise to identify what the flaws are in any given
indirect comparison or network meta-analysis, let
alone whether the code used in the analysis was
correct.
Currently it is seen as a “strange, peculiar” method,
and somewhat mistrusted
I think it’s moving in the right direction really – NICE
support them, because they’re a ‘necessary evil’ –
there’s a well known disconnect between the trial
design required for licensing, and that for the
evidence base needed for reimbursement and clinical
decision making. People maybe still see it as ‘voodoo’
but in general I think we at least in the UK have a
reasonably good and established process for selecting
the best evidence available to inform decision making.
We currently stand at a crossroads where policy
makers are content for indirect comparisons to be
undertaken for the purposes of health economic
evaluation. However, a fundamental shift in
understanding needs to take place so that decision
makers (policy makers/clinicians and in time the
general public) accept the validity of the estimates of
safety/efficacy that come from the analysis in their
own right. In particular, indirect comparisons appear
to have the same “face validity” to clinicians as
pairwise meta-analysis did 15+ years ago.
Discussion
To my knowledge, this is the first published survey
reporting the attitudes of systematic review authors who
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have used NMA methods to reporting standards for
such research.
This survey found that systematic review authors who
have used NMA methods did so mainly because of the
lack of direct trial data or because of the ability to com-
pare and rank multiple interventions. Authors who have
used these methods are mostly inclined to use them
again. Their responses demonstrated strong support for
adoption of standards for conduct and reporting of
NMA. The elements of reporting standards proposed
by these authors are substantially consistent with
those reported by Hutton [10, 11] as part of the devel-
opment work for and final publication of the extension
of the PRISMA statement. This should augur well for
adoption of that extension, suggesting that it will carry
the support of authors publishing this form of meta-
analysis. Support in principle for the content of a
reporting guideline does not however necessarily
translate into compliance [15]. Whilst several responders
to the survey made the observation that reporting
standards should include those required for pairwise
meta-analysis, most reported that they had not followed
any reporting guideline.
A notable theme arising from the responses was the
tension between, on the one hand, a view that the use of
NMA should be more easily accessible, particularly in
the form of software tools, and on the other, concerns
that there is some inappropriate use of the methods
which wider use and greater accessibility could exacer-
bate. This tension prompts the question: what is the
ability of the end users (clinicians, commissioners, policy
makers) to critically appraise and interpret the results
produced using this methodology? Adoption of stan-
dards for conduct and reporting will be significant
steps towards clarifying what is appropriate use and
what is not. I suggest this should be followed by the de-
velopment of a critical appraisal tool to further support
end users.
Limitations of the survey
The respondents formed a minority of the authors
approached and the views of non-respondents are un-
known. Nevertheless, there was no apparent bias in
those responding in terms of year of publication or in
the number or subject of reviews published. Conduct-
ing the survey by email afforded limited opportunity
to clarify responses and did not allow me to pursue
lines of enquiry, so the responses are what authors
chose to volunteer and therefore cannot be assumed
to represent all their opinions. The author is a part-time re-
search student, researching reporting standards and critical
appraisal criteria for network meta-analyses reported
in systematic reviews. Survey questions made specific
mention of reporting guidelines, which may have influ-
enced the mention of these in responses. My research
interests influenced the questions and are likely to
have influenced both the selection of responses I have
quoted and my overall interpretation of all responses;
however, I approached this survey without pre-conceived
expectations of what the responses would be but with
the hope that the responses might identify specific is-
sues or themes that would be suitable for further
exploration.
Conclusions
Authors demonstrated strong support for adoption of
standards for conduct and reporting of network meta-
analysis. The elements of reporting standards proposed
are consistent with those included in the 2015 PRISMA
extension statement. As more widespread use of the
methods continues to develop, it should be accompan-
ied by assurance that use is appropriate. Adoption of
standards for conduct and reporting will be a signifi-
cant step towards clarifying what is appropriate use of
the methods and what is not. This should be followed
by the development of a critical appraisal tool to support




1 Why did you choose an indirect comparison
method for meta-analysis in your review?
2 If you were repeating the review in future, would
you choose an indirect comparison method again?
If you would not, please explain why.
3 Please name any reporting guideline(s) you followed
when reporting the indirect comparison and the
review.
4 What, in your opinion, are the essential details to
include for accurate and reliable reporting of
indirect comparison in a review?
5 Please name any reporting guideline(s) that, in your
opinion, includes the essential details for accurate
and reliable reporting of indirect comparison in a
review.
6 What is (are), in your opinion, the most important
development(s) needed to support the conduct,
reporting and use of indirect comparison methods?
7 What would encourage further use of indirect
comparison methods by reviewers?
8 What would encourage further use of evidence from
reviews reporting indirect comparison methods by
decision makers (including policy makers, clinical
practitioners and the public)?
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